Safety of intradermal administration of monosodium urate crystals as a carrier of idiotype cancer vaccine
Not Applicable
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000001624
- Lead Sponsor
- ational Hospital Organization Awara Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) Adolecents having major organ injury indicated by elevated level of serum creatinine, total bilirubin or ALT , or having symptomatic congestive heart failure 2) Patients suffering from gout 3) Patients with any of active autoimmune disease 4) Patients with any of active infectious disease 5) Women on (possible) pregnancy or lactation 6) Adolecents judged inadequate by doctor in charge of the patient or the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safetiness during three weeks following the administration of monosodium urate crystals
- Secondary Outcome Measures
Name Time Method Serum level of inflammatory cytokines Decndritic cell count in the peripheral blood